<?xml version="1.0" encoding="UTF-8"?>
<p>According to the Stanford HIVdb v7.0, predicted resistance to the first-line drugs among the patients with TDR was 75% intermediate- to high-level resistance to efavirenz and nevirapine (recommended first-line NNRTI drugs), 25% to the cytosine analogues; lamivudine and emtricitabine and about 13% to tenofovir, abacavir, stavudine and didanosine (recommended NRTI drugs), and rilpivirine and etravirine (NNRTI drugs). None of the patients had intermediate- to high-level resistance to zidovudine or PI drugs (
 <xref rid="pone.0171124.t003" ref-type="table">Table 3</xref> and 
 <xref ref-type="fig" rid="pone.0171124.g001">Fig 1</xref>).
</p>
